Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
Oct 4 AZN Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
Oct 4 AZN AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
Oct 4 GTLS ExxonMobil Selects Chart Industries’ IPSMR® Liquefaction Process Technology and Proprietary Equipment
Oct 4 GTLS Chart Industries to Announce Third Quarter 2024 Results on November 1
Oct 4 AZN Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules
Oct 4 APLS Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)
Oct 4 AZN How to minimise a capital gains tax impact on your investments
Oct 3 GTLS Navigating 9 Analyst Ratings For Chart Industries
Oct 3 AZN AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
Oct 3 AZN AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
Oct 3 APLS Should You Hold Apellis Pharmaceuticals (APLS)?
Oct 3 AZN AstraZeneca supplemental NDA for Calquence accepted by FDA
Oct 3 AZN U.S. tweaks 2025 Medicare price negotiation process
Oct 3 AZN AstraZeneca Says Calquence Granted FDA Priority Review in Mantle Cell Lymphoma
Oct 3 AZN CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
Oct 3 AZN Owkin and AstraZeneca to develop AI tool for breast cancer testing
Oct 3 AZN Arcus and AstraZeneca enter trial collaboration for renal cancer treatment
Oct 3 AZN 3 UK Stocks Estimated To Be Trading Below Their Intrinsic Value
Oct 2 IXHL Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Oct 2 OPK Here's Why You Should Retain OPKO Health Stock in Your Portfolio
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags